Swedbank AB Has $132.74 Million Holdings in Amgen Inc. $AMGN

Swedbank AB reduced its position in Amgen Inc. (NASDAQ:AMGN) by 16.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 405,559 shares of the medical research company’s stock after selling 79,844 shares during the period. Swedbank AB’s holdings in Amgen were worth $132,744,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of AMGN. Capital World Investors increased its position in Amgen by 11.5% in the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock worth $5,303,578,000 after purchasing an additional 1,935,876 shares during the last quarter. Vanguard Group Inc. increased its position in Amgen by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after purchasing an additional 961,975 shares during the last quarter. National Bank of Canada FI increased its position in Amgen by 237.7% in the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after purchasing an additional 863,216 shares during the last quarter. Van ECK Associates Corp increased its position in Amgen by 71.8% in the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock worth $383,254,000 after purchasing an additional 567,400 shares during the last quarter. Finally, Fisher Asset Management LLC increased its position in Amgen by 91.6% in the 3rd quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company’s stock worth $221,607,000 after purchasing an additional 375,463 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Leerink Partners reaffirmed a “market perform” rating and issued a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. Barclays assumed coverage on Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price objective on the stock. UBS Group increased their price objective on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a report on Monday, April 13th. Morgan Stanley set a $332.00 price objective on Amgen in a report on Friday, May 1st. Finally, Guggenheim lowered their price objective on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a report on Monday, May 4th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $355.19.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen expanded its lung cancer pipeline by launching a phase 1b study testing a tarlatamab combination in small cell lung cancer, which could improve the company’s oncology growth prospects if the data are encouraging. Amgen Expands Lung Cancer Pipeline With New Tarlatamab Combo Study
• Positive Sentiment: Several reports highlighted Amgen as a long-term value/dividend and pipeline story, citing upside potential and analyst support such as an Overweight rating from Piper Sandler, reinforcing confidence in the company’s revenue growth outlook. Why Wall Street Thinks This Dividend Stock Could Jump 30%
• Positive Sentiment: Amgen shareholders reaffirmed the board, executive pay and auditors, which signals governance stability and removes a potential overhang. Amgen Shareholders Reaffirm Board, Pay and Auditors
• Neutral Sentiment: Amgen appointed Thomas Dittrich as chief financial officer, a management update that should be watched for any strategic or capital-allocation changes, but is not clearly a near-term stock catalyst. CFOs On the Move: Week ending May 22
• Negative Sentiment: Investor focus remains on safety concerns around Tavneos after reported patient deaths in Japan prompted restrictions on new prescriptions and raised the risk of withdrawal requests in the U.S., creating a potential earnings and sentiment headwind for Amgen. A Look At Amgen (AMGN) Valuation As Tavneos Safety Concerns And Withdrawal Requests Escalate
• Negative Sentiment: News that doctors in Japan could again prescribe Tavneos to new patients only partially eases concerns, because the drug still carries liver-injury warnings and the broader safety controversy may continue to pressure sentiment. Doctors in Japan can again prescribe an Amgen rare-disease drug to new patients, reversing a recommendation made only days ago following 20 deaths

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.85% of the company’s stock.

Amgen Price Performance

Amgen stock opened at $339.30 on Friday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The company has a market capitalization of $183.11 billion, a PE ratio of 23.61, a price-to-earnings-growth ratio of 3.41 and a beta of 0.44. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29. The business has a 50 day simple moving average of $345.10 and a 200 day simple moving average of $344.38.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, sell-side analysts forecast that Amgen Inc. will post 22.37 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s dividend payout ratio (DPR) is 70.15%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.